Dr. Mitchell Steiner, Chief Executive Officer of GTx, Inc., presides over the opening bell.

Tuesday September 4, 2007
from Nasdaq MarketSite
in New York's Times Square

GTx, Inc.

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx has initiated a Phase IIb Ostarine(TM) clinical trial for cancer cachexia and plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis. GTx is also developing two other product candidates, GTx-838, another GTx SARM, for the treatment of sarcopenia, and GTx-878, an estrogen receptor beta agonist for the treatment of benign prostatic hyperplasia and chronic prostatitis. GTx is planning to file an Investigational New Drug application (IND) with the FDA for GTx-838 by year end 2007 and to file an IND for GTx-878 during 2008.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 09/04/2007 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Dr. Mitchell Steiner, Chief Executive Officer of GTx, Inc., presides over the opening bell. Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at Jolene.Libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission. © Copyright 2007, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.